{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T07:45:56Z","timestamp":1780472756890,"version":"3.54.1"},"reference-count":16,"publisher":"The Journal of Rheumatology","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Rheumatol"],"published-print":{"date-parts":[[2010,4]]},"abstract":"<jats:sec><jats:title>Objective.<\/jats:title><jats:p>To compare the incidence of liver toxicity and clinical response between 2 initial dosing regimens of methotrexate (MTX) for treatment of juvenile idiopathic arthritis (JIA).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods.<\/jats:title><jats:p>Clinical and laboratory data were abstracted from the medical records of 220 children newly prescribed MTX from the same geographic region. One cohort received initial doses of MTX &gt; 0.5 mg\/kg\/week (\u201chigh-dose\u201d) and one cohort received initial doses of MTX \u2264 0.5 mg\/kg\/week (\u201clow-dose\u201d). Toxicity was defined as aspartate aminotransferase (AST) and\/or alanine aminotransferase (ALT) above the normal range, and positive clinical response was defined as a reduction in active joint count during the first 6 months of MTX therapy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results.<\/jats:title><jats:p>One hundred twenty-six children were in the high-dose MTX group, 94 in the low-dose MTX group. At 6 months, the high-dose group was more likely to have an elevated AST or ALT (adjusted OR 3.89, 95% CI 1.82\u20138.29, p &lt; 0.0001). Subjects receiving both MTX and nonsteroidal antiinflammatory drugs (NSAID) had no significant difference between groups in change of active joint count, while subjects in the high-dose group but not taking NSAID had more active joints (p = 0.036) at 6 months compared to the low-dose group.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion.<\/jats:title><jats:p>Initial high-dose MTX was associated with an increased risk of at least one liver enzyme abnormality with no significant improvement in active joint count. This suggests that there is no apparent benefit, while the potential for liver toxicity is increased, when using higher doses of MTX at treatment inception in patients with JIA.<\/jats:p><\/jats:sec>","DOI":"10.3899\/jrheum.090826","type":"journal-article","created":{"date-parts":[[2010,3,2]],"date-time":"2010-03-02T03:55:01Z","timestamp":1267502101000},"page":"870-875","source":"Crossref","is-referenced-by-count":37,"title":["Effectiveness and Toxicity of Methotrexate in Juvenile Idiopathic Arthritis: Comparison of 2 Initial Dosing Regimens"],"prefix":"10.3899","volume":"37","author":[{"given":"MARA L.","family":"BECKER","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"CARLOS D.","family":"ROS\u00c9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"RANDY Q.","family":"CRON","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"DAVID D.","family":"SHERRY","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"WARREN B.","family":"BILKER","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"EBBING","family":"LAUTENBACH","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2262","published-online":{"date-parts":[[2010,3,1]]},"reference":[{"key":"2018112909224107000_37.4.870.1","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1002\/art.1780290616","article-title":"Methotrexate therapy in juvenile rheumatoid arthritis: A retrospective study","volume":"29","author":"Truckenbrodt","year":"1986","journal-title":"Arthritis Rheum"},{"key":"2018112909224107000_37.4.870.2","first-page":"647","article-title":"Low dose methotrexate in systemic onset juvenile chronic arthritis","volume":"7","author":"Speckmaier","year":"1989","journal-title":"Clin Exp Rheumatol"},{"key":"2018112909224107000_37.4.870.3","first-page":"118","article-title":"Predicting remission in juvenile rheumatoid arthritis with methotrexate treatment","volume":"23","author":"Wallace","year":"1993","journal-title":"J Rheumatol"},{"key":"2018112909224107000_37.4.870.4","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3476(05)80709-7"},{"key":"2018112909224107000_37.4.870.5","first-page":"297","article-title":"Evaluation of methotrexate in the treatment of juvenile chronic arthritis according to subtype","volume":"9","author":"Halle","year":"1991","journal-title":"Clin Exp Rheumatol"},{"key":"2018112909224107000_37.4.870.6","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1056\/NEJM199204163261602","article-title":"Methotrexate in resistant juvenile rheumatoid arthritis: results of the USA-USSR double-blind, placebo-controlled trial","volume":"326","author":"Giannini","year":"1992","journal-title":"N Engl J Med"},{"key":"2018112909224107000_37.4.870.7","first-page":"1604","article-title":"Preliminary report of higher dose methotrexate treatment in juvenile rheumatoid arthritis","volume":"19","author":"Wallace","year":"1992","journal-title":"J Rheumatol"},{"key":"2018112909224107000_37.4.870.8","first-page":"113","article-title":"High dose methotrexate in the treatment of refractory juvenile rheumatoid arthritis","volume":"13","author":"Reiff","year":"1995","journal-title":"Clin Exp Rheumatol"},{"key":"2018112909224107000_37.4.870.9","doi-asserted-by":"publisher","DOI":"10.1002\/art.20288"},{"key":"2018112909224107000_37.4.870.10","first-page":"390","article-title":"International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: Second revision, Edmonton, 2001","volume":"31","author":"Petty","year":"2004","journal-title":"J Rheumatol"},{"key":"2018112909224107000_37.4.870.11","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1002\/art.1780370304","article-title":"Methotrexate for rheumatoid arthritis: Suggested guidelines for monitoring liver toxicity","volume":"37","author":"Kremer","year":"1994","journal-title":"Arthritis Rheum"},{"key":"2018112909224107000_37.4.870.12","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1002\/1529-0131(199707)40:7<1202::AID-ART3>3.0.CO;2-R","article-title":"Preliminary definition of improvement in juvenile arthritis","volume":"40","author":"Giannini","year":"1997","journal-title":"Arthritis Rheum"},{"key":"2018112909224107000_37.4.870.13","doi-asserted-by":"crossref","first-page":"2226","DOI":"10.1002\/art.1780401218","article-title":"The long term effect of methotrexate therapy on the liver in patients with juvenile rheumatoid arthritis","volume":"40","author":"Hashkes","year":"1997","journal-title":"Arthritis Rheum"},{"key":"2018112909224107000_37.4.870.14","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3476(99)70371-9"},{"key":"2018112909224107000_37.4.870.15","first-page":"2442","article-title":"Hepatotoxicity in patients with juvenile idiopathic arthritis receiving long term methotrexate therapy","volume":"29","author":"Lahdenne","year":"2002","journal-title":"J Rheumatol"},{"key":"2018112909224107000_37.4.870.16","first-page":"2501","article-title":"Guidelines for blood test monitoring of methotrexate toxicity in juvenile idiopathic arthritis","volume":"31","author":"Ortiz-Alvarez","year":"2004","journal-title":"J Rheumatol"}],"container-title":["The Journal of Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.3899\/jrheum.090826","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,11,29]],"date-time":"2018-11-29T17:38:14Z","timestamp":1543513094000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jrheum.org\/lookup\/doi\/10.3899\/jrheum.090826"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,3,1]]},"references-count":16,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2010,4,1]]},"published-print":{"date-parts":[[2010,4]]}},"alternative-id":["10.3899\/jrheum.090826"],"URL":"https:\/\/doi.org\/10.3899\/jrheum.090826","relation":{},"ISSN":["0315-162X","1499-2752"],"issn-type":[{"value":"0315-162X","type":"print"},{"value":"1499-2752","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,3,1]]}}}